about
Diet composition as a source of variation in experimental animal models of cancer cachexiaPotential Biomarkers of Fat Loss as a Feature of Cancer CachexiaInfluence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexiaUnderstanding and managing cancer cachexia.N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome.Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy.Nutritional interventions for cancer-induced cachexiaMeasurement of skeletal muscle radiation attenuation and basis of its biological variation.Increased catabolism and decreased unsaturation of ganglioside in patients with inflammatory bowel disease.Inflammation, obesity, and fatty acid metabolism: influence of n-3 polyunsaturated fatty acids on factors contributing to metabolic syndrome.n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia.n-3 polyunsaturated fatty acids: the potential role for supplementation in cancer.Role of n-3 fatty acids in muscle loss and myosteatosis.Evidence and mechanisms of fat depletion in cancer.Prevalence of inadequate vitamin d status and associated factors in children with cystic fibrosis.Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes.Clinical Implications of Sarcopenic Obesity in Cancer.Does Persistent Inflammatory Catabolic Syndrome Exist in Critically Ill Neonates?Visceral adiposity and cancer survival: a review of imaging studies.Surgical fasting guidelines in children: Are we putting them into practice?Reduced growth and integrin expression of prostate cells cultured with lycopene, vitamin E and fish oil in vitro.Subcutaneous adiposity is an independent predictor of mortality in cancer patients.Indicators of Pediatric Malnutrition in a Tertiary Care Hospital.Glucagon-Like Peptide-2 Alters Bile Acid Metabolism in Parenteral Nutrition--Associated Liver Disease.Reduction of Arachidonate Is Associated With Increase in B-Cell Activation Marker in Infants: A Randomized Trial.Fish oil mitigates myosteatosis and improves chemotherapy efficacy in a preclinical model of colon cancerDietary ganglioside reduces proinflammatory signaling in the intestine.Epidemiology of interruptions to nutrition support in critically ill children in the pediatric intensive care unit.A fishy conclusion regarding n-3 fatty acid supplementation in cancer patients.Aberrations in plasma phospholipid fatty acids in lung cancer patients.Fasting triacylglycerol status, but not polyunsaturated/saturated fatty acid ratio, influences the postprandial response to a series of oral fat tolerance tests.Long-chain polyunsaturated fat supplementation in children with low docosahexaenoic acid intakes alters immune phenotypes compared with placebo.Ganglioside Intake Increases Plasma Ganglioside Content in Human Participants.New oral fat tolerance tests feature tailoring of the polyunsaturated/saturated fatty acid ratio to elicit a specific postprandial response.Recommended European Society of Parenteral and Enteral Nutrition protein and energy intakes and weight loss in patients with head and neck cancer.A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease.Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content.Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancerLoss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients
P50
Q26738879-78F4760E-133B-4299-BAF6-D74EE8A2F7B3Q26778319-E6B49519-D16E-40D8-9701-A65DECBF6FF7Q26827510-F5BE124E-689F-496D-B53B-93F680CACD7CQ33966821-4784F281-F2FB-4976-8222-D5019087D4EAQ34330782-EDED1585-5D9B-4743-BF29-073C4E826B4BQ34627257-0E9AD1DF-FE2A-4E82-8A41-07F5EFB07D84Q35019743-13A668EF-2423-4808-AA47-A97CEDE4C9A6Q35023332-C4D98E34-EF65-4059-B3E2-ABC12F52EE03Q36067567-90685CBF-640D-4C6D-BE05-65152B3988FEQ37024566-E80E5D89-5B1A-4A55-865A-E2DDE5B01716Q37350075-6712E18F-3AD4-4256-BD73-85477140C1E8Q37988336-889F1A11-33B2-461A-BF50-9EC8AB5F62E7Q38215558-A8CC68AE-B253-4300-815B-AAFC56CAEEC5Q38270323-7B05EEBE-64A3-4236-980E-F1B14A58543BQ38304351-5AAA66AE-6E67-4C95-941E-1B82868FCAC9Q38581850-E1696DC5-7509-4EA1-831F-540C71A1A9D6Q38931979-D25B0900-6FFC-40A7-A14A-7D682D8E4F35Q39016674-0EAA44A7-CD04-44B6-B843-EE51879673AFQ39030345-B8A61C39-2949-4826-808E-9471F756D062Q39776145-8954106C-F0A0-4EC8-9E7A-2554D268D753Q39948673-926023ED-2850-4D7D-BDBE-8F697BF0AF8BQ40170188-9900949E-8E0D-4A7F-BBDC-55C3DA0C1576Q40287701-1A97BB43-7E03-42C9-9BB2-3B13E1C9EA47Q40684817-CB16D2C0-DAFC-423E-9D7F-6B571E20791CQ40712218-D4A88978-8EA4-4B6B-8306-2872908FD023Q41498645-0E2D3FDC-06E0-4F44-9D50-478A3545C3C2Q42108943-C95E3B1C-BE8F-4932-9202-688FBDE2B470Q43861131-EBE118EA-41BC-4C17-B870-A17445D2B890Q44884654-DF796739-B87B-40BD-B134-258FAB69FCE8Q44968492-9CE3A7EF-39DF-43EB-A221-ACEDAD984588Q46336673-054AA7D1-9BFF-413C-A005-145FF43D1C4EQ46584862-91BA086B-BE40-4091-B3F7-D9C064D81274Q46623333-3E532BDB-52CF-489B-A9F6-B922F9DE03D4Q46865917-5DF780DB-7860-428E-BDD2-42185EEBF267Q47314940-242389D3-B722-4C2E-A385-DCDA2A0D1492Q51347859-E5893471-D9C5-42B5-B3FA-1CFEF127FFE4Q51350582-7AD839F7-90D7-4C81-A262-3B82F95BEADCQ52984361-8D0E3100-ED44-4163-8FA0-249D4CA6AF16Q57314892-84F3858C-9B68-4AB7-B545-8CEEF2F6C140Q57314897-5D90EFD4-5FFD-4C3A-8984-E8768E546503
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vera C. Mazurak
@ast
Vera C. Mazurak
@en
Vera C. Mazurak
@es
Vera C. Mazurak
@nl
Vera C. Mazurak
@sl
type
label
Vera C. Mazurak
@ast
Vera C. Mazurak
@en
Vera C. Mazurak
@es
Vera C. Mazurak
@nl
Vera C. Mazurak
@sl
prefLabel
Vera C. Mazurak
@ast
Vera C. Mazurak
@en
Vera C. Mazurak
@es
Vera C. Mazurak
@nl
Vera C. Mazurak
@sl
P1053
J-5136-2014
P106
P1153
8787877500
P21
P31
P3829
P496
0000-0002-7724-6354